ClinicalTrials.gg

Program

avexitide

Also written as “Avexitide” and “exendin 9-39”.

Its studies are mostly in Hypoglycemia, led by 2 companies.

Furthest: phase 3, since Dec 18, 20242 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amylyx Pharmaceuticals11 open or runningphase 3since Dec 18, 2024Dec 18, 2024none ahead
Eiger BioPharmaceuticals10 open or runningphase 2since Nov 27, 2017Nov 27, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2017First study: phase 2 study in Postbariatric HypoglycemiaNew to Eiger BioPharmaceuticalsEiger BioPharmaceuticals · NCT03373435 · 18 enrolled · United States
  2. Dec 18, 2024Amylyx Pharmaceuticals’ first study: phase 3 study in HypoglycemiaNew to Amylyx PharmaceuticalsAmylyx Pharmaceuticals · NCT06747468 · 75 enrolled · United States

TargetBeta

GLP1R →read by rule
“A truncated form of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 peptide, with GLP-1 receptor (GLP-1R) antagonistic and GLP-1R-mediated signaling inhibiting activities”NCIt, by rule
“Glucagon-like peptide 1 receptor antagonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06747468Hypoglycemia · United States3Active, not recruitingAmylyx PharmaceuticalsJul 8, 202675
NCT03373435Postbariatric Hypoglycemia · United States2CompletedEiger BioPharmaceuticalsJan 30, 201918

How it is read

Names in the registry

  • “Avexitide”, 1 entry
  • “exendin 9-39”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.